BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29938300)

  • 1. Guidelines on nuclear medicine imaging in neuroblastoma.
    Bar-Sever Z; Biassoni L; Shulkin B; Kong G; Hofman MS; Lopci E; Manea I; Koziorowski J; Castellani R; Boubaker A; Lambert B; Pfluger T; Nadel H; Sharp S; Giammarile F
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):2009-2024. PubMed ID: 29938300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Medicine in Pediatric and Adolescent Tumors.
    Kiratli PÖ; Tuncel M; Bar-Sever Z
    Semin Nucl Med; 2016 Jul; 46(4):308-23. PubMed ID: 27237441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments.
    Samim A; Tytgat GAM; Bleeker G; Wenker STM; Chatalic KLS; Poot AJ; Tolboom N; van Noesel MM; Lam MGEH; de Keizer B
    J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33916640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.
    Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG
    Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
    Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
    Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
    Piccardo A; Treglia G; Fiz F; Bar-Sever Z; Bottoni G; Biassoni L; Borgwardt L; de Keizer B; Jehanno N; Lopci E; Kurch L; Massollo M; Nadel H; Roca Bielsa I; Shulkin B; Vali R; De Palma D; Cecchin D; Santos AI; Zucchetta P
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):756-767. PubMed ID: 37962616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Samim A; Blom T; Poot AJ; Windhorst AD; Fiocco M; Tolboom N; Braat AJAT; Viol SLM; van Rooij R; van Noesel MM; Lam MGEH; Tytgat GAM; de Keizer B
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1146-1157. PubMed ID: 36504277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
    Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
    J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
    Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
    Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theranostics in Neuroblastoma.
    Rafael MS; Cohen-Gogo S; Irwin MS; Vali R; Shammas A; Morgenstern DA
    PET Clin; 2021 Jul; 16(3):419-427. PubMed ID: 34053585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
    Colavolpe C; Guedj E; Cammilleri S; Taïeb D; Mundler O; Coze C
    Pediatr Blood Cancer; 2008 Dec; 51(6):828-31. PubMed ID: 18680162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weak uptake of 123I-MIBG and 18F-FDOPA contrasting with high 18F-FDG uptake in stage I neuroblastoma.
    Wartski M; Jehanno N; Michon J; de Labriolle-Vaylet C; Montravers F
    Clin Nucl Med; 2015 Dec; 40(12):969-70. PubMed ID: 26544903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
    Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT imaging in neuroblastoma.
    Piccardo A; Lopci E; Conte M; Foppiani L; Garaventa A; Cabria M; Villavecchia G; Fanti S; Cistaro A
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):29-39. PubMed ID: 23474633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy.
    Boubaker A; Bischof Delaloye A
    Q J Nucl Med; 2003 Mar; 47(1):31-40. PubMed ID: 12714952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts on the diagnostic use of MIBG in children.
    Shulkin BL; Shapiro B
    J Nucl Med; 1998 Apr; 39(4):679-88. PubMed ID: 9544682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.
    Feng L; Li S; Wang C; Yang J
    Semin Nucl Med; 2023 Jul; 53(4):517-529. PubMed ID: 36682980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional-metabolic imaging of neuroblastoma.
    Sharp SE; Parisi MT; Gelfand MJ; Yanik GA; Shulkin BL
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):6-20. PubMed ID: 23474631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.